Compare Adaptive Biotechnologies Corp (ADPT) vs Crown Castle International Corp (CCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Crown Castle International Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Crown Castle International Corp trades at $76.96 (market cap $33.70B). The key difference: Crown Castle International Corp is far larger — about 10.1× Adaptive Biotechnologies Corp's market cap, and Crown Castle International Corp pays a 5.5% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CCI | |
|---|---|---|
Market Cap | $3.33B | $33.70B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $113.91 |
52-Week Low | $10.24 | $74.92 |
Enterprise Value | $3.19B | $63.53B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Crown Castle (CCI) trades at $77.22, up 0.81% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q1 2026 miss but strong beats in prior quarters, while the company transitions to a pure-play U.S. tower focus after divesting its fiber business. Cash flow remains positive, but high debt levels and negative shareholder equity pose challenges. The stock is near its 52-week low, with a consensus price target of $97.33 suggesting significant upside potential.
The outlook for CCI hinges on execution of its strategic refocus and cost reductions. Opportunities include a 5.55% dividend yield and analyst optimism, but risks from elevated leverage and competitive pressures in telecom infrastructure warrant caution. Investor sentiment is divided, with technical indicators signaling near-term weakness despite long-term value arguments from bulls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
